Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Role of Rapid Virologic Response in Determining Treatment Duration of Peginterferon Alfa-2b/Ribavirin in Chronic Hepatitis C Genotype 4
NCT00277862Phase 4Completed
- Sponsor
- Ain Shams University
- Start
- Apr 2002
- Primary completion
- Mar 2007
- Modality
- Polymer-based Nanoparticles, Orthosteric Ligands, Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 4, randomised trial of peginterferon alfa-2b and ribavirin in hepatitis C (HCV) (4 arms), sponsored by Ain Shams University. Primary endpoint: Sustained Virologic Response at 18 months. Started Apr 2002; status: completed.
02
Drugs
peginterferon alfa-2bribavirin
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT00277862.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00277862.